Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma

BACKGROUND. Patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) demonstrate aberrant activation of the phosphotidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway. We examined the efficacy of everolimus, an mTOR inhibitor, in patients with recur...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Head Neck
Main Authors: Geiger, Jessica L., Bauman, Julie E., Gibson, Michael K., Gooding, William E., Varadarajan, Prakash, Kotsakis, Athanasios, Martin, Daniel, Gutkind, Jorge Silvio, Hedberg, Matthew L., Grandis, Jennifer R., Argiris, Athanassios
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6820341/
https://ncbi.nlm.nih.gov/pubmed/27232378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.24501
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados